Zobrazeno 1 - 10
of 526
pro vyhledávání: '"exon 20 insertion"'
Publikováno v:
Chinese Journal of Lung Cancer, Vol 27, Iss 8, Pp 579-592 (2024)
In non-small cell lung cancer (NSCLC), as an improtant oncogenic driver gene, epidermal growth factor receptor exon 20 insertion (EGFR ex20ins) has a unique protein structure and is primarily drug-resistant to traditional EGFR-tyrosine kinase inhibit
Externí odkaz:
https://doaj.org/article/14db8ff83ea041c09e185facf69febc8
Publikováno v:
Chinese Journal of Lung Cancer, Vol 27, Iss 3, Pp 241-244 (2024)
With the continuous innovation of genomics, proteomics and molecular biological detection technology, the treatment of non-small cell lung cancer (NSCLC) has changed from traditional chemotherapy to immunotherapy and targeted therapy. Among them, mol
Externí odkaz:
https://doaj.org/article/6569d7d40a5f48e8b286bdd55a430cbf
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations are the third most prevalent mutation in non-small cell lung cancer (NSCLC), following the 19del and L858R mutations. The unique nature of the EGFR ex20ins mutation poses c
Externí odkaz:
https://doaj.org/article/45d2613161a145d6a49103d340e70671
Autor:
Maximilian J. Hochmair, Mojca Unk, Jelena Spasic, Timur Cerić, Assia Konsoulova, Mircea Dediu, Krisztina Bogos, Alinta Hegmane, Kersti Oselin, Marko Stojiljkovic, Tina Roblek, Marko Jakopovic
Publikováno v:
BMC Proceedings, Vol 18, Iss S3, Pp 1-7 (2024)
Abstract Lung cancer remains the leading cause of cancer-related deaths in Europe, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. NSCLC is a heterogeneous disease encompassing various oncogenic alterations. Among t
Externí odkaz:
https://doaj.org/article/f9f7e046c374460e862662228b2b71f4
Autor:
Hai‐Yan Tu, Kai Yin, Xiaotian Zhao, E‐E Ke, Si‐Pei Wu, Yang‐Si Li, Mei‐Mei Zheng, Si‐Yang Maggie Liu, Chong‐Rui Xu, Yue‐Li Sun, Jia‐Xin Lin, Xiao‐Yan Bai, Yi‐Chen Zhang, Qing Zhou, Jin‐Ji Yang, Wen‐Zhao Zhong, Bing‐Chao Wang, Xu‐Chao Zhang, Dongqin Zhu, Lingling Yang, Qiuxiang Ou, Yi‐Long Wu
Publikováno v:
Molecular Oncology, Vol 17, Iss 8, Pp 1581-1594 (2023)
The efficacy of immunotherapy in advanced HER2‐mutated non‐small‐cell lung cancer (NSCLC) remains incomprehensively studied. A total of 107 NSCLC patients with de novo HER2 mutations were retrospectively studied at Guangdong Lung Cancer Institu
Externí odkaz:
https://doaj.org/article/d5aadd22e14b45079cd59c661d0f474c
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Recently, targeted therapy and immunotherapy have emerged as effective treatment options for non-small cell lung cancer (NSCLC). This progress has been facilitated by the rapid development of diagnostic and therapeutic technologies and the continuous
Externí odkaz:
https://doaj.org/article/15acd1ee8af3412f9c2fc240cacb5459
Publikováno v:
Heliyon, Vol 10, Iss 9, Pp e30312- (2024)
A775_G776insYVMA, the typical and predominant HER2 exon 20 insertion variant in non-small cell lung cancer, exhibits relative insensitivity to covalent HER2-targeted tyrosine kinase inhibitors. However, other less common insertions have shown better
Externí odkaz:
https://doaj.org/article/1c07e257f4354db0be44f596c74d1d84
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThe epidermal growth factor receptor (EGFR) ex20ins mutation, as a rare subtype of mutation, has gradually attracted attention. Its heterogeneity is high, its prognosis is extremely poor, and the efficacy of existing traditional treatment p
Externí odkaz:
https://doaj.org/article/8b9cc7bad5ca4050aff51c2d9a1e8a76
Publikováno v:
Current Oncology, Vol 30, Iss 11, Pp 9929-9939 (2023)
Background: EGFR and ERBB2 exon 20 insertion (Ex20ins) account for a small fraction of patients with EGFR mutations. The efficacy of immune checkpoint inhibitors (ICIs) for these patients was still controversial. Methods: This retrospective study enr
Externí odkaz:
https://doaj.org/article/8ea350d643ec478b94d0a1ab205e11db
Autor:
Chen Shi, Cong Zhang, Zhiwen Fu, Jinmei Liu, Yuanfeng Zhou, Bao Cheng, Cong Wang, Shijun Li, Yu Zhang
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 13, Iss 6, Pp 2613-2627 (2023)
Uncommon epidermal growth factor receptor (EGFR) mutations account for 10%–20% of all EGFR mutations in non-small-cell lung cancer (NSCLC). The uncommon EGFR-mutated NSCLC is associated with poor clinical outcomes and generally achieved unsatisfact
Externí odkaz:
https://doaj.org/article/042083c0f0b24c0e8de95297a5585825